$76.990
+0.023 (+0.03%)Zum Schluss
FBRX-News
FBRX-Events
Wedbush Raises Argenx Price Target to $1,050 and Acquires Forte
Wedbush raised the firm's price target on Argenx (ARGX) to $1,050 from $1,000 and keeps an Outperform rating on the shares. The firm notes the company will acquire Forte Biosciences (FBRX) for $77/share in cash, adding FB102, a first-in-class anti-CD122 antibody, to its growing immunology pipeline. The transaction follows Argenx's strategic investment in Forte's April financing at $26.27/share and reflects management's continued strategy of selectively acquiring differentiated immunology assets with broad pipeline-in-a-product potential. The acquisition is supported by encouraging early proof-of-concept across two autoimmune diseases, Wedbush adds.
Dow Rises, Nasdaq Falls as Market Focuses on Economic Data
The major averages had a mixed day, with the Dow and the S&P 500 higher and Nasdaq in decline amid weakness in tech stocks as the market has reacted positively to easing geopolitical tensions and a steep decline in oil prices.Investor attention is focused on a week that includes the Federal Reserve's July policy meeting, second-quarter GDP data, the June personal consumption expenditures price index, and earnings from four of the "Magnificent Seven" companies. The combination of major economic data and heavyweight earnings is expected to drive market direction through the end of the week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Appleis lobbying the Trump administration to let it use Chinese memory chips, while U.S. supplier Micronis pushing to block the move,ArgenxForte Biosciencesfor $77 per share in cashNaver, Nvidia, and Brookfieldannounced a proposed expansion of, with planned investments that will grow the initial Nvidia DSX AI factory deployment to 200 megawattsMeanwhile, Nvidia is in talks to provide a $250B backstop for OpenAI,Baker Hughesreported2. WALL STREET CALLS:JefferiesFordand General Motorsto BuyRivianto Overweight at Piper SandlerStellantisto Underweight from Overweight at Piper SandlerJPMorganCheck Pointon weaker competitive positionWall Streetcoverage of Bending Spoonswith a mix of Buy and Hold-equivalent ratings3. AROUND THE WEB:Fordhas entered the competition to build the U.S. Army's next-generation tactical truck, WSJ reportsA Chinese state-backed company has begun manufacturing immersion deep ultraviolet lithography machines, a key type of equipment used by chipmakers like TSMCin producing chips, The Information saysParamount Skydanceand Warner Bros. Discoveryremain in limbo as their $81B merger faces an antitrust review that could delay the deal into 2027, limiting strategic moves while the companies focus on legal proceedings and competitors continue to expand, WSJ saysUniCreditCEO Andrea Orcel sees room for an agreement over the bank's proposed takeover of Commerzbank, signaling confidence discussions with the government and stakeholders could lead to a deal, Bloomberg saysTrip.comhas been fined $765M by Chinese regulators after it was concluded that the company abused its market dominance, Bloomberg reports4. MOVERS:D-Wave Quantumgained afterwith AT&TOmerosincreased after AstraZenecareportedof ultomirisGenius Sportswas higher in New York after Goldman Sachscoverage of the stock with a Buy ratingCapricor Therapeuticswas lower after the FDAMapLight Therapeuticsfell after announcing results from its5. EARNINGS/GUIDANCE:AstraZenecaand reaffirmed its guidance for FY26, with CEO Pascal Soriot commenting on "strong performance and continued pipeline delivery" in the first halfEnsign Groupand raised its outlook for FY26Bank of Marin, with EPS beating consensusBank of Hawaii, with CEO Jim Polk calling them "solid"Sierra Bancorp, with EPS missing consensusINDEXES:The Dow rose 262.83, or 0.51%, to 52,210.08, the Nasdaq lost 43.74, or 0.18%, to 24,932.08, and the S&P 500 advanced 1.20, or 0.02%, to 7,413.18.
Argenx Acquires Forte for $77/Share, H.C. Wainwright Bullish on First Tracks
After Argenx (ARGX) announced a deal to acquire Forte (FBRX) for a price of $77 per share, a 43% premium to Friday's share price and a total equity value of $2.2B, H.C. Wainwright said the firm views the Forte acquisition as "highly relevant" for First Tracks Biotherapeutics (TRAX). Forte's anti-CD122 antibody, FB102, is a direct competitor for First Tracks' ANB033 asset, which is in development for celiac disease and eosinophilic esophagitis, notes the analyst, who believes the rival acquisition news "bodes well for ANB033 and makes First Tracks a potential acquisition target, assuming Phase 1b CeD data are positive." The firm has a Buy rating on First Tracks and says it is evaluating its estimates and valuation assumptions based on today's news.
Dow Rises While Nasdaq Falls; Market Focused on Economic Data
The major averages were mixed near noon, with the Dow higher and the S&P 500 and Nasdaq in decline amid weakness in tech stocks. Still, the market has reacted positively to easing geopolitical tensions and a steep decline in oil prices.Investor attention is focused on a week that includes the Federal Reserve's July policy meeting, second-quarter GDP data, the June personal consumption expenditures price index, and earnings from four of the "Magnificent Seven" companies. The combination of major economic data and heavyweight earnings is expected to drive market direction through the end of the week.Get caught up quickly on the top news and calls moving stocks with these five Top Five lists.1. STOCK NEWS:Appleis lobbying the Trump administration to let it use Chinese memory chips, while U.S. supplier Micronis pushing to block the move,ArgenxForte Biosciencesfor $77 per share in cashNaver, Nvidia, and Brookfieldannounced a proposed expansion of, with planned investments that will grow the initial Nvidia DSX AI factory deployment to 200 megawattsMeanwhile, Nvidia is in talks to provide a $250B backstop for OpenAI,Baker Hughesreported2. WALL STREET CALLS:JefferiesFordand General Motorsto BuyRivianto Overweight at Piper SandlerStellantisto Underweight from Overweight at Piper SandlerJPMorganCheck Pointon weaker competitive positionWall Streetof Bending Spoonswith a mix of Buy and Hold-equivalent ratings3. AROUND THE WEB:A Chinese state-backed company has begun manufacturing immersion deep ultraviolet lithography machines, a key type of equipment used by chipmakers like TSMCin producing chips, The Information saysParamount Skydanceand Warner Bros. Discoveryremain in limbo as their $81B merger faces an antitrust review that could delay the deal into 2027, limiting strategic moves while the companies focus on legal proceedings and competitors continue to expand, WSJ saysUniCreditCEO Andrea Orcel sees room for an agreement over the bank's proposed takeover of Commerzbank, signaling confidence discussions with the government and stakeholders could lead to a deal, Bloomberg saysWaymo'srobotaxis have been fined $9,325 in parking tickets in Austin since 2024, WSJ reportsTrip.comhas been fined $765M by Chinese regulators after it was concluded that the company abused its market dominance, Bloomberg reports4. MOVERS:D-Wave Quantumgains afterwith AT&T (T)Omerosincreases afterfrom its Phase 3 study of ultomirisGenius Sportshigher in New York after Goldman Sachsof the stock with a Buy ratingCapricor Therapeuticslower after thefor deramiocelMapLight Therapeutics (MPLT) falls afterfrom its ZEPHYR trial evaluating ML-007C-MA5. EARNINGS/GUIDANCE:AstraZenecaand reaffirmed its guidance for FY26, with CEO Pascal Soriot commenting, "In the first half we saw strong performance and continued pipeline delivery"Ensign Groupand raised its outlook for FY26Bank of Marin (BMRC), with EPS beating consensusBank of Hawaii, with CEO Jim Polk calling them "solid"Sierra Bancorp, with EPS missing consensusINDEXES:Near midday, the Dow was up 90.71, or 0.17%, to 52,037.96, the Nasdaq was down 144.56, or 0.58%, to 24,831.27, and the S&P 500 was down 19.66, or 0.27%, to 7,392.32.
Stock Futures Surge as Oil Prices Plunge
Stock futures are sharply higher Monday as investors return from the weekend encouraged by easing geopolitical tensions and a steep decline in oil prices. Dow, S&P 500 and Nasdaq futures are all advancing ahead of the opening bell, with technology and travel stocks leading premarket gains as crude prices retreat.Markets are reacting positively to reports that the Trump administration has paused further military escalation with Iran to allow room for diplomatic efforts. The easing in tensions has sent Brent crude sharply lower, relieving concerns that higher energy prices could fuel inflation and complicate the Federal Reserve's policy outlook. Airline, cruise and other travel-related stocks are benefiting from the drop in oil, while energy shares are under pressure.Investor attention is focused on a week that includes the Federal Reserve's July policy meeting, second-quarter GDP data, the June personal consumption expenditures price index, and earnings from four of the "Magnificent Seven" companies. The combination of major economic data and heavyweight earnings is expected to drive market direction through the end of the week.Following last week's mixed market reaction to Alphabet and Tesla, results from Microsoft, Meta, Amazon and Apple are expected to provide the clearest indication yet of whether the AI-driven rally can regain momentum.In pre-market trading, S&P 500 futures rose 0.89%, Nasdaq futures rose 1.42% and Dow futures rose 1.15%.Check out this morning's top movers from around Wall Street, compiled by The Fly.HIGHER -Forte Biosciencesup 40% after entering into a definitive agreement under which Argenxwill acquire the company for $77 per share in cashGossamer Bioup 28% after proceeding toward a planned NDA submission for seralutinib for the treatment of patients with PAH in September and reacquiring worldwide development and commercial rights to seralutinib from ChiesiD-Wave Quantumup 9% after AT&Tannounced an agreement to expand its use of D-Wave's quantum computing technology and plans to use the technology to address complex optimization challenges across its network operationsUP AFTER EARNINGS -Ensign Groupup 11%Baker Hughesup 3%AstraZenecaup 1%DOWN AFTER EARNINGS -Alpha Metallurgicaldown 4%Alliance Resource Partnersdown 1%LOWER -MapLight Therapeuticsdown 62% after reporting topline results from its Phase 2 ZEPHYR trial evaluating ML-007C-MA, an oral M1/M4 muscarinic agonist co-formulated with a peripherally acting anticholinergic, in adults with an acute exacerbation of schizophreniaArgenxdown 1% after entering into an agreement to acquire Forte Biosciences for $77 per share in cash
Diese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.